Latest Antiandrogens Stories
HORSHAM, Pa., May 25, 2011 /PRNewswire/ -- A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA(TM) (abiraterone acetate) plus prednisone compared to patients treated with prednisone plus placebo.
WASHINGTON, May 16, 2011 /PRNewswire/ -- A poster entitled, "Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment," is being presented at the American Urological Association 2011 meeting by E.
HORSHAM, Pa., April 28, 2011 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the U.S.
SILVER SPRING, Md., April 28, 2011 /PRNewswire-USNewswire/ -- The U.S.
Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids.
SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo.
WASHINGTON, Oct. 1 /PRNewswire-USNewswire/ -- U.S. Centers for Disease Control and Prevention officials have disclosed that two mifepristone (RU-486)-induced deaths occurred in the past two years, bringing the total number of reported death related to RU-486 to 12.
SAN FRANCISCO and TOKYO, Sept. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
LOS ANGELES, Sept.
- A woman chauffeur.
- A woman who operates an automobile.